Integration of molecular biological techniques and behavioural pharmacology

Behavioural Pharmacology

Volumn 7, Issue 7, 1996, Pages 589-615

  Gold, L H ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

antisense oligonucleotides; behavioural pharmacology; knockout mutations; molecular biology; transgenic animals

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; AMPHETAMINE; ANTISENSE OLIGONUCLEOTIDE; CHOLINERGIC RECEPTOR; DOPAMINE RECEPTOR; MORPHINE; NEUROTRANSMITTER; NEUROTRANSMITTER RECEPTOR; PSYCHOTROPIC AGENT; RECEPTOR SUBUNIT; SEROTONIN RECEPTOR;

ANIMAL MODEL; BEHAVIOR; GENE EXPRESSION; GENE TARGETING; GENOTYPE; METHODOLOGY; MOLECULAR BIOLOGY; MUTATION; NEUROPATHOLOGY; NEUROPSYCHIATRY; NEUROSCIENCE; NONHUMAN; PHARMACOLOGY; REVIEW; TECHNOLOGY; TRANSGENIC ANIMAL;

EID: 0030431522     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-199611000-00004     Document Type: Review

References (163)

1. Abeliovich A, Paylor R, Chen C, Kim J, Wehner J and Tonegawa S (1993) PKCγ mutant mice exhibit mild deficits in spatial and contextual learning. Cell, 75, 1263-1271.
2. Accili D, Fishburn C, Drago J, Lachowicz J, Steiner H, Park B, Gauda E, Lee E, Cool M, Gerfen C, Sibley D, Westphal H and Fuchs S (1995) D3 dopamine receptor knock-out mice. Society for Neuroscience Abstracts, 21, 364.
3. Adams JU, Chen X, DeRiel JK, Adler MW and Liu-Chen L-Y (1994) Intracerebroventricular treatment with an antisense oligodeoxynucleotide to κ-opioid receptors inhibited κ-agonist-induced analgesia in rats. Brain Research, 667, 129-132.
4. Aguzzi A, Brandner S, Sure U, Ruedi D and Isenmann S (1994) Transgenic and knock-out mice: Models of neurological disease. Brain Pathology, 4, 3-20.
5. Aiba A, Chen C, Herrup K, Rosenmund C, Stevens C and Tonegawa S (1994a) Reduced hippocampal long-term potentiation and context-specific deficit in associative learning in mGluR1 mutant mice. Cell, 79, 365-375.
6. Aiba A, Kano M, Chen C, Stanton M, Fox G, Herrup K, Zwingman T and Tonegawa S (1994b) Deficient cerebellar long-term depression and impaired motor learning in mGluR1 mutant mice. Cell, 79, 377-388.
7. Akabayashi A, Wahlestedt C, Alexander J and Leibowitz S (1994) Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligonucleotides suppresses feeding behaviour and insulin secretion. Molecular Brain Research, 21, 55-61.
8. Bach M, Hawkins R, Osman M, Kandel E and Mayford M (1995) Impairment of spatial but not contextual memory in CaMKII mutant mice with a selective loss of hippocampal LTP in the range of the θ frequency. Cell, 81, 905-915.
9. Baik J, Picetti R, Saiardi A, Thiriet G, Dierich A, Depaulis A, Le Meur M and Borrelli E (1995) Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature, 377, 424-428.
10. Beaulieu S, Rousse I, Gratton A, Barden N and Rochford J (1994) Behavioral and endocrine impact of impaired type II glucocorticoid receptor function in a transgenic mouse model. Annals of the New York Academy of Sciences, 746, 388-391.
11. Behan PD, Heinrichs SC, Troncoso JC, Liu X-J, Kawas CH, Ling N and DeSouza EB (1995) Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer's disease. Nature, 378, 284-287.
12. Bennett CF (1996) Antisense research. Science, 271, 434.
13. Bergman J, Kamien JB and Spealman RD (1990) Antagonism of cocaine self-administration by selective dopamine D1 and D2 antagonists. Behavioural Pharmacology, 1, 355-363.
14. 4] deltorphin antinociception by supraspinal, but not spinal, administration of an antisense oligodeoxynucleotide to an opioid delta receptor. Life Sciences, 55, 37-43.
15. Blaha D and Phillips AG (1996) A critical assessment of electrochemical procedures applied to the measurement of dopamine and its metabolites during drug-induced and species-typical behaviours. Behaviour Pharmacology, 1, 675-708.
16. Borsook D, Falkowski O, Rosen H, Comb M and Hyman S (1994) Opioids modulate stress-induced proenkephalin gene expression in the hypothalamus of transgenic mice: a model of endogenous opioid gene regulation by exogenous opioids. Journal of Neuroscience, 14, 7261-7271.
17. 6 receptor in the rat brain: a study using antisense oligonucleotides. Journal of Pharmacology and Experimental Therapeutics, 274, 173-180.
18. Bourtchuladze R, Frenguelli B, Blendy J, Cioffi D, Schutz G and Silva A (1994) Deficient long-term memory in mice with a targeted mutation of the cAMP-responsive element-binding protein. Cell, 79, 59-68.
19. Bovet D, Bovet-Nitti F and Oliverio A (1969) Genetic aspects of learning and memory in mice. Science, 163, 139-149.
20. Brandon EP, Idzerda RL and McKnight GS (1995a) Knockouts. Targeting the mouse genome: a compendium of knockouts (Part I). Current Biology, 5, 625-634.
21. Brandon EP, Idzerda RL and McKnight GS (1995b) Targeting the mouse genome: a compendium of knockouts (Part II). Current Biology, 5, 758-765.
22. Brandon EP, Idzerda RL and McKnight GS (1995c) Targeting the mouse genome: a compendium of knockouts (Part III). Current Biology, 5, 873-881.
23. Byrne GW and Ruddle FH (1989) Multiplex gene regulation: a two-tiered approach to transgene regulation in transgenic mice. Proceedings of the National Academy of Sciences, 86, 5473-5477.
24. Cadd G, Hoyle G, Quiafe C, Marck B, Matsumoto A, Brinster R and Palmiter R (1992) Alteration of neurotransmitter phenotype in noradrenergic neurons of transgenic mice. Molecular Endocrinology, 6, 1951-1960.
25. Cadet J, Ladenheim B, Baum I, Carlson E and Epstein C (1994) CuZn-superoxide dismutase (CuZnSOD) transgenic mice show resistance to the lethal effects of methylenedioxyamphetamine (MDA) and of methylenedioxymethamphetamine (MDMA). Brain Research, 655, 259-262.
26. Caine SB and Koob GF (1993) Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science, 260, 1814-1816.
27. Caine SB, Gold LH, Koob GF, Deroche V, Heyser C, Polis I, Roberts A, Xu M and Tonegawa S (1995) Intravenous cocaine self-administered in mice: strain differences and effects of D-1 dopamine receptor targeted gene mutation. Society of Neuroscience Abstracts, 21, 719.
28. Campbell IL and Gold LH (1996) Transgenic modeling of neuropsychiatric disorders. Molecular Psychiatry, 1, 105-120.
29. Campbell IL and Powell HC (1996) Role of cytokines in demyelinating disease studied in transgenic mice. In: Methods: A Companion to Methods in Enzymology, (Ed J Merrill), Vol. 10, pp. 462-477, Academic Press, San Diego.
30. Capecchi M (1989) Altering the genome by homologous recombination. Science, 244, 1288-1292.
31. Capecchi M (1994) Targeted gene replacement. Scientific American, 270, 52-59.
32. Cases O, Seif I, Grimsby J, Gaspar P, Chen K, Pournin S, Müller U, Aguet M, Babinet C, Shih JC and De Maeyer E (1995) Aggressive behavior and altered amounts of brain serotonin and morepinephine in mice lacking MAOA. Science, 268, 1763-1766.
33. Chatterjee S, Steger R, Yun J, Wagner T, Bartke A and Banerji T (1989) Hypothalamic catecholamine content and the activities of dopamine-β-hydroxylase and phenylethanolamine-N-methyltransferase in transgenic mice bearing the gene for human growth hormone. Neuroendocrinology Letters, 5, 311-317.
34. Chen C, Rainnie D, Greene R and Tonegawa S (1994) Abnormal fear response and aggressive behavior in mutant mice deficient for α-calcium-calmodulin kinase II. Science, 266, 291-294.
35. Chen X-H, Adams JU, Geller EB, DeRiel JK, Adler MW and Liu-Chen L-Y (1995a) An antisense oligodeoxynucleotide to μ-opioid receptors inhibits μ-opioid receptor agonist-induced analgesia in rats. European Journal of Pharmacology, 275, 105-108.
36. Chen X-H, Geller EB, deRiel JK, Liu-Chen L-Y and Adler MW (1995b) Antisense oligodeoxynucleotides against μ- or κ-opioid receptors block agonist-induced body temperature changes in rats. Brain Research, 688, 237-241.
37. Chiasson BJ, Hooper ML, Murphy PR and Robertson HA (1992) Antisense oligonucleotide eliminates in vivo expression of c-fos in mammalian brain. European Journal of Pharmacology, 227, 451-453.
38. Conquet F, Bashir Z, Davies C, Daniel H, Ferraguti F, Bordi F, Franz-Bacon K, Reggiani A, Matarese V, Conde F, Collingridge G and Crepel F (1994) Motor deficit and impairment of synaptic plasticity in mice lacking mGluR1. Nature, 372, 237-243.
39. Cooper D, Hu X, Xu M, Tonegawa S and White F (1995) Behavioural sensitization to cocaine in dopamine D1 receptor deficient mice: involvement of serotonin. Society for Neuroscience Abstracts, 21, 364.
40. Crabbe J, Belknap J and Buck K (1994) Genetic animal models of alcohol and drug abuse. Science, 264, 1715-1723.
41. Crawley JN and Davis LG (1982) Baseline exploratory activity predicts anxiolytic responsiveness to diazepam in five mouse strains. Brain Research Bulletin, 8, 609-612.
42. Davies R, Gallagher E and Savioz A (1994) Reverse genetics of the mouse central nervous system: targeted gene analysis of neuropeptide function and reverse genetic screens for genes involved in human neurodegenerative disease. Progress in Neurobiology, 42, 319-331.
43. Di Chiara G, Tanda G and Carboni E (1996) Estimation of in vivo neurotransmitter release by brain microdialysis: the issue of validity. Behavioural Pharmacology, 1, 640-657.
44. Donovan D, Miner L, Sora I, Mulle J, Prezedboroski S, Jackson-Lewis V, Izenwasser S, Rothman R, Dersch C and Ulh G (1995) Transgenic mice with differential dopamine transporter expression. Society for Neuroscience Abstracts, 21, 1380.
45. 1A dopamine receptors. Proceedings of the National Academy of Sciences, 91, 12564-12568.
46. Dulawa SC, Hen R, Scearce K and Geyer MA (1995) Characterization of serotonin 1B receptor contribution to startle amplitude and prepulse inhibition in wild type and serotonin IB minus mice. Society for Neuroscience Abstracts, 21, 1693.
47. Dunn AJ and Berridge CW (1990) Physiological and behavioural responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Research Reviews, 15, 71-100.
48. Elmer GI and George FR (1995) Genetic differences in the operant rate-depressant effects of ethanol between four inbred mouse strains. Behavioural Pharmacology, 6, 794-800.
49. Elmer GI, Evans JL, Goldberg SR, Epstein CJ and Cadet JL (1995a) Morphine self-administration behavior in transgenic super-oxide dismutase mice. Society of Neuroscience Abstracts, 21, 730.
50. Elmer GI, Evans JL, Ladenheim B, Epstein CJ and Cadel JL (1995b) Transgenic superoxide dismutase mice differ in opioid-induced analgesia. European Journal of Pharmacology, 283, 227-232.
51. Elmer GI, Pieper JO, Goldberg SR and George FR (1995c) Opioid operant self-administration, analgesia, stimulation and respiratory depression in μ-deficient mice. Psychopharmacology, 117, 23-31.
52. Furth P, Onge L, Boger H, Gruss P, Gossen M, Kistner A, Bujard H and Henninghausen L (1994) Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proceedings of the National Academy of Sciences, 91, 9302-9306.
53. Giros B, Jaber M, Jones SR, Wightman RM and Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature, 379, 606-612.
54. Gossen M and Bujard H (1992) Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proceedings of the National Academy of Sciences, 89, 5547-5551.
55. Gordon JW and Ruddle FH (1983) Gene transfer into mouse embryos: production of transgenic mice by pronuclear injection. Methods in Enzymology, 101, 411-433.
56. Grailhe R and Hen R (1995) 5-HT knockouts: constitutive, inducible or tissue-specific. Seminars in the Neurosciences, 7, 395-400.
57. Grant S (1994) Gene targeting and synaptic plasticity. Current Opinion in Neurobiology, 4, 687-692.
58. Grant S, O'Dell T, Karl K, Stein P, Soriano P and Kandel E (1992) Impaired long-term potentiation, spatial learning, and hippocampal development in fyn mutant mice. Science, 258, 1903-1910.
59. Grisel J, Grahame N, Mogil J, Belknap J and Low M (1995) Decreased voluntary ethanol consumption in transgenic mice lacking β-endorphin. Society for Neuroscience Abstracts, 21, 1699.
60. Gu H, Marth J, Orban P, Mossman H and Rajewsky K (1994) Deletion of a DNA polymerase β gene segment in T cells using cell type-specific gene targeting. Science, 265, 103-106.
61. Gura T (1995) Antisense has growing pains. Science, 270, 575-577.
62. Heilig M (1995) Antisense inhibition of neuropeptide Y (NPY)-Y1 receptor expression blocks the anxolytic-like action of NPY in amygdala and paradoxically increases feeding. Regulatory Peptides, 59, 210-205.
63. Heilig M, Engel J and Soderpalm B (1993) C-fos antisense in the nucleus accumbens blocks the locomotor stimulant action of cocaine. European Journal of Pharmacology, 236, 339-340.
64. Heinrichs SC, Menzaghi F, Pich EM, Baldwin HA, Rassnick S, Britton KT and Koob GF (1994) Anti-stress action of a corticotropin-releasing factor antagonist on behavioral reactivity to stressors of varying type and intensity. Neuropsychopharmacology, 11, 179-186.
65. Heinrichs S, Stenzel-Poore M, Gold L, Battenberg E, Bloom F, Koob G, Vale W and Pich E (1996) Learning impairment in transgenic mice with central overexpression of corticotropin-releasing factor. Neuroscience, 74, 303-311.
66. Helene C and Toulme J (1990) Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochemica el Biophysica Acta, 1049, 99-125.
67. Hess EJ, Collins KA and Wilson MC (1996) Mouse model of hyperkinesis implicates SNAP-25 in behavioral regulation. The Journal of Neuroscience, 16, 3104-3111.
68. Hilakivi-Clarke L, Arora P, Sabol M, Clarke R, Dickson R and Lippman M (1992) Alterations in behavior, steroid hormones and natural killer cell activity in male transgenic TGF α mice. Brain Research, 588, 97.
69. Hilakivi-Clarke L, Durcan M and Goldberg R (1993) Effect of alcohol on elevated aggressive behavior in male transgenic TGF α mice. NeuroReport, 4, 155-158.
70. Hilakivi-Clarke L and Goldberg R (1993) Effects of tryptophan and serotonin uptake inhibitors on behavior in male transgenic transforming growth factor α mice. European Journal of Pharmacology, 237, 101-108.
71. Hooper M, Chiasson B and Robertson H (1994) Infusion into the brain of an antisense oligonucleotide to the immediateearly gene c-fos suppresses production of FOS and produces a behavioral effect. Neuroscience, 63, 917-924.
72. Hulsey MG, Pless CM, White BD and Martin RJ (1995) ICV administration of anti-NPY antisense oligonucleotide: effects on feeding behavior, body weight, peptide content and peptide release. Regulatory Peptides, 59, 207-214.
73. Jaenisch R (1988) Transgenic animals. Science, 240, 1468-1474.
74. Kalin NH, Sherman JE and Takahashi LK (1988) Antagonism of endogenous CRH systems attenuates stress-induced freezing behavior in rats. Brain Research, 457, 130-135.
75. Kiuchi K, Kiuchi K, Kaneda N, Sasoka T, Hidaka H and Nagatsu T (1993) Regulatory mechanism of dopamine biosynthesis in the striatum of transgenic mice carrying human tyrosine hydroxylase gene. Neuroscience Letters, 151, 55-58.
76. Kobayashi K, Morita S, Mizuguchi T, Sawada H, Yamada K, Nagatsu I, Fujita K and Nagatsu T (1994) Functional and high level expression of human dopamine β-hydroxylase in transgenic mice. Journal of Biological Chemistry, 269, 29725-29731.
77. Koeltzow T, Cooper D, Hu X, Xu M, Tonegawa S and White F (1995) In vivo effects of dopaminergic ligands in dopamine D3 receptor deficient mice. Society for Neuroscience Abstracts, 21, 364.
78. Konradi C, Cole R, Heckers S and Hyman S (1994) Amphetamine regulates gene expression in rat striatum via transcription factor CREB. Journal of Neuroscience, 14, 5623-5634.
79. Koob GF (1991) Behavioral responses to stress. Focus on corticotropin-releasing factor. In: Stress. Neurobiology and Neuroendocrinology, (Eds MR Brown, GF Koob and C Rivier), pp. 255-271. Marcel Dekker Inc., New York.
80. Koob GF, Le HT and Creese I (1987) D-1 receptor antagonist SCH 23390 increases cocaine self-administration in the rat. Neuroscience Letters, 79, 315-321.
81. Kuhn R, Schwenk F, Aguet M and Rajewsky K (1995) Inducible gene targeting in mice. Science, 269, 1427-1429.
82. Kujirai K, Carlson E, Epstein CJ and Cadet JL (1994) Autoradiographic distribution of mu opioid receptors in brains of Cu/Zn-superoxide dismutase mice. Synapse, 17, 76-83.
83. 2-agonist antinociception. NeuroReport, 5, 1049.
84. Lai J, Bilsky E and Porreca F (1995) Treatment with antisense oligodeoxynucleotide to a conserved sequence of opioid receptors inhibits antinociceptive effects of delta subtype selective ligands. Journal of Receptor and Signal Transduction Research, 15, 643-650.
85. Landgraf R, Gerstberger R, Montkowski A, Probst JC, Wotjak CT, Holsboer F and Engelmann M (1995) V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats. Journal of Neuroscience, 15, 4250-4258.
86. Liebsch G, Landgraf R, Gerstberger R, Probst JC, Wotjak CT, Engelmann M, Holsboer F and Montkowski A (1995) Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regulatory Peptides, 59, 229-239.
87. Loke S, Stein C, Zhang X, More K, Nakanishi M, Subasinghe C, Cohen J and Neckers L (1989) Characterization of oligonucleotide transport into living cells. Proceedings of the National Academy of Sciences, 86, 3474-3478.
88. Mani SK, Allen JMC, Clark JH, Blaustein JD and O'Malley BW (1994) Convergent pathways for steroid hormone- and neurotransmitter-induced rat sexual behavior. Science, 265, 1246-1249.
89. Mansour S, Thomas K and Capecchi M (1988) Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes. Nature, 336, 348-352.
90. Marks MJ, Stitzel JA and Collins AC (1989) Genetic influences on nicotine responses. Pharmacology Biochemistry and Behavior, 33, 667-678.
91. Mayford M. Abel T and Kandel ER (1995a) Transgenic approaches to cognition. Current Opinion in Neurobiology, 5, 141-148.
92. Mayford M, Wang J, Kandel ER and O'Dell TJ (1995b) CaM-KII regulates the frequency-response function of hippocampal synapses for the production of both LTD and LTP. Cell, 81, 891-904.
93. McCarthy MM, Kleopoulos SP, Mobbs CV and Pfaff DW (1994) Infusion of antisense oligodeoxynucleotides to the oxytocin receptor in the ventromedial hypothalamus reduces estrogen-induced sexual receptivity and oxytocin receptor binding in the female rat. Neuroendocrinology, 59, 432-440.
94. Meliska C, Bartke A, Vandergriff J and Jensen R (1995) Ethanol and nicotine consumption and preference in transgenic mice overexpressing the bovine growth hormone gene. Pharmacology Biochemistry and Behavior, 50, 563-570.
95. Merlino G (1991) Transgenic animals in biomedical research. FASEB Journal, 5, 2996-3001.
96. Miner L, Drago J, Chamberlain P, Donovan D and Uhl G (1995a) Retained cocaine conditioned place preference in D1 receptor deficient mice. NeuroReport, 6, 2314-2316.
97. Miner L, Sharpe L, Elmer G, Sora I, Donovan D, Mulle J, Moriwaki A, Wang J and Uhl G (1995b) μ-Opiate receptor: regional transgene overexpression alters opiate responses. Society for Neuroscience Abstracts, 21, 724.
98. Miyakawa T, Yagi T, Watanabe S and Niki H (1994) Increased fearfulness of Fyn tyrosine kinase deficient mice. Molecular Brain Research, 27, 179-182.
99. Moller C, Bing O and Heilig M (1994) c-fos Expression in the amygdala: in vivo antisense modulation and role in anxiety. Cellular and Molecular Neurobiology, 14, 415-423.
100. Montkowski A, Barden N, Wotjak C, Stec I, Ganster J, Meaney M, Engelmann M, Reul JMHM, Landgraf R and Holsboer F (1995) Long-term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function. Journal of Neuroendocrinology, 7, 841-845.
101. Morita S, Kobayashi K, Mizuguchi T, Yamada K, Nagatsu I, Titani K, Fujita K, Hidaka H and Nagatsu T (1993) The 5′-flanking region of the human dopamine β-hydroxylase gene promotes neuron subtype-specific gene expression in the central nervous system of transgenic mice. Molecular Brain Research, 17, 239-244.
102. Morris M and Lucion A (1995) Antisense oligonucleotides in the study of neuroendocrine systems. Journal of Neuroendocrinology, 1, 493-500.
103. Mucke L, Masliah E and Campbell IL (1995) Transgenic mouse models to assess the neuropathogenic potential of HIV-1 proteins. Current Topics in Microbiology and Immunology, 202, 187-205.
104. Muglia L, Jacobson L, Dikkes P and Majzoub J (1995) Corticotropin-releasing hormone deficiency reveals major fetal but not adult glucocorticoid need. Nature, 373, 427-432.
105. Murphy D and Carter DA (1993) Transgenesis Techniques: Principles and Protocols, Humana Press, Totowa.
106. Nelson R, Demas G, Huang P, Fishman M, Dawson V, Dawson T and Snyder S (1995) Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase. Nature, 378, 383-386.
107. Nissbrandt H, Ekman A, Eriksson E and Heilig M (1995) Dopamine D3 receptor antisense influences dopamine synthesis in rat brain. NeuroReport, 6, 573-576.
108. O'Dell TJ, Huang PL, Dawson TM, Dinerman JL, Snyder SH, Kandel ER and Fishman MC (1994) Endothelial NOS and the blockade of LTP by NOS inhibitors in mice lacking neuronal NOS. Science, 265, 542-546.
109. Ogawa S, Olazabal UE, Parhar IS and Pfaff DW (1994) Effects of intrahypothalamic administration of antisense DNA for progesterone receptor mRNA on reproductive behavior and progesterone receptor immunoreactivity in female rat. Journal of Neuroscience, 14, 1766-1774.
110. Owens MJ and Nemeroff CB (1991) Physiology and pharmacology of corticotropin-releasing factor. Pharmacological Reviews, 43, 425-473.
111. Palmiter R and Brinster RL (1986) Germ-line transformation of mice. Annual Review of Genetics, 20, 465-99.
112. Pasternak GW, Pan Y-X and Cheng J (1995) Correlating the pharmacology and molecular biology of opioid receptors. Cloning and antisense mapping a kappa 3-related opiate receptor. Annals of the New York Academy of Sciences, 757, 332-338.
113. Pepin M, Pothier F and Barden N (1992) Impaired type II glucocorticoid-receptor function in mice bearing antisense RNA transgene. Nature, 355, 725-728.
114. Phillips H (1996) Use of transgenics and knockouts. Seminars in The Neurosciences, 8, 115-116.
115. Phillips MI (1995) Antisense oligonucleotides in in vivo regulatory peptide research. Regulatory Peptides. 59, iii-v.
116. Phillips MI and Gyurko R (1995) In vivo applications of antisense oligonucleotides for peptide research. Regulatory Peptides, 59, 131-141.
117. Picciotto M, Zoli M, Lena C, Bessis A, Lallemand Y, LeNovere N, Vincent P, Pich E, Brulet P and Changeux J (1995) Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature, 374, 65-67.
118. Pinkert C (1994) Transgenic Animal Technology: a Laboratory Handbook Academic Press, San Diego.
119. Raffa RB, Martinez RP and Connelly CD (1994) G-protein antisense oligodeoxyribonucleotides and μ-opioid supraspinal antinociception. European Journal of Pharmacology, 258, R5-R7.
120. Readhead C, Popko B, Takahashi N, Shine HD, Saavedra RA, Sidman RL and Hood L (1987) Expression of a myelin basic protein gene in transgenic shiverer mice: correction of the dysmyelinating phenotype. Cell, 48, 703-712.
121. Sakai RR, He PF, Yang XD, Ma LY, Guo YF, Reilly JJ, Moga CN and Fluharty SJ (1994) Intracerebroventricular administration of AT1 receptor antisense oligonucleotides inhibits the behavioral actions of angiotensin II. Journal of Neurochemistry, 62, 2053-2056.
122. 1B receptor. Science, 265, 1875-1878.
123. Self DW and Nestler EJ (1995) Molecular mechanisms of drug reinforcement and addiction. Annual Review of Neuroscience, 18, 463-495.
124. Self DW and Stein L (1992) The D1 agonists SKF 82958 and SKF 77434 are self-administered by rats. Brain Research, 582, 349-352.
125. Silva A, Paylor R, Wehner J and Tonegawa S (1992a) Impaired spatial learning in α-calcium-calmodulin kinase II mutant mice. Science, 257, 206-211.
126. Silvia A, Stevens C, Tonegawa S and Wang Y (1992b) Deficient hippocampal long-term potentiation in α-calcium-calmodulin kinase II mutant mice. Science, 257, 201-205.
127. 2 autoreceptors in the motor actions of cocaine. Molecular Pharmacology, 46, 51-57.
128. Skutella T, Montkowski A, Stohr T, Probst J, Landgraf R, Holsboer F and Jirikowski G (1994a) Corticotropin-releasing hormone (CRH) antisense oligodeoxynucleotide treatment attenuates social defeat-induced anxiety in rats. Cellular and Molecular Neurobiology, 14, 579-588.
129. Skutella T, Probst J, Jirikowski G, Holsboer F and Spanagel R (1994b) Ventral tegmental area (VTA) injections of tyrosine hydroxylase phosphorothioate antisense oligonucleotide suppress operant behavior in rats. Neuroscience Letters, 167, 55-58.
130. Smithies O, Gregg RG, Boggs SS, Koralewski MA and Kucherlapati RS (1985) Insertion of DNA sequences into the human chromosome β-globin locus by homologous recombination. Nature, 317, 230-234.
131. Smithies O and Maeda N (1995) Gene targeting approaches to complex genetic diseases: atherosclerosis and essential hypertension. Proceedings of the National Academy of Sciences, 92, 5266-5272.
132. Sommer W, Bjelke B, Ganten D and Fuxe K (1993) Antisense oligonucleotide to c-fos induces ipsilateral rotational behaviour to d-amphetamine. NeuroReport, 5, 277-280.
133. Standifer KM, Chien C-C, Wahlestedt C, Brown GP and Pasternak GW (1994) Selective loss of δ opioid analgesia and binding by antisense oligodeoxynucleotides to a δ opioid receptor. Neuron, 12, 808-810.
134. Stein C and Cheng Y (1993) Antisense oligonucleotides as therapeutic agents - is the bullet really magical. Science, 261, 1004-1012.
135. Stenzel-Poore M, Heinrichs S, Rivest S, Koob G and Vale W (1994) Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. Journal of Neuroscience, 14, 2579-2584.
136. Takahashi J, Pinto L and Vitaterna M (1994) Forward and reverse genetic approaches to behavior in the mouse. Science, 264, 1724-1733.
137. 2C serotonin receptors. Nature, 374, 542-546.
138. Tecott LH, Brennan TJ and Guh L (1996) Gene targeting approaches to analyze neurotransmitter receptor function. Seminars in The Neurosciences, 8, 145-152.
139. Thomas KR and Capecchi MR (1986) Introduction of homologous DNA sequences into mammalian cells induces mutations in the cognate gene. Nature, 324, 34-38.
140. Thomas K and Capecchi M (1987) Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell, 51, 503-512.
141. Thompson WR (1956) Activity differences in five inbred mouse strains. Journal of Heredity, 47, 147-148.
142. Tonegawa S (1995) Mammalian learning and memory studied by gene targeting. Annals of the New York Academy of Sciences, 758, 213-217.
143. Tseng LF, Collins KA and Kampine JP (1994) Antisense oligodeoxynucleotide to a δ-opioid receptor selectively blocks the spinal antinociception induced by δ-, but not μ- or κ-opioid receptor agonists in the mouse. European Journal of Pharmacology, 258, R1-R3.
144. 5]enkephalin antiserum-sensitive enhancement of morphine antinociception. NeuroReport, 5, 2601-2605.
145. Vaupel DB, Kimes AS and London ED (1995) Nitric oxide synthase inhibitors: preclinical studies for potential use for treatment of opioid withdrawal. Neuropsychopharmacology, 13, 315-322.
146. Waddington JL, Daly SA, Downes RP, Deveney AM, McCauley PG and O'Boyle KM (1995) Behavioural pharmacology of 'D1-like' dopamine receptors: further subtyping, new pharmacological probes and interactions with 'D2-like' receptors. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 19, 811-831.
147. Wahlestedt C (1994) Antisense oligonucleotide strategies in neuropharmacology. Trends in Pharmacological Sciences, 15, 42-45.
148. Wahlestedt C, Golanov E, Yamamoto S, Yee F, Ericson H, Yoo H, Inturrisi C and Reis D (1993a) Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons form excitotoxicity and reduce focal ischaemic infarctions. Nature, 363, 260-263.
149. Wahlestedt C, Pich E, Koob G, Yee F and Heilig M (1993b) Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science, 259, 528-531.
150. Wahlsten D (1972) Genetic experiments with animal learning: a critical review. Behavioral Biology, 7, 143-182.
151. Weed MR and Woolverton WL (1995) The reinforcing effects of dopamine D1 receptor agonists in rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics, 275, 1367-1374.
152. 2 messenger RNA. Neuroscience, 55, 607-612.
153. Wehner JM and Bowers BJ (1995) Use of transgenics, null mutants, and antisense approaches to study ethanol's actions. Alcoholism: Clinical and Experimental Research, 19, 811-820.
154. Whitesell L, Geselowitz D, Chavany C, Fahmy B, Walbridge S, Alger J and Neckers L (1993) Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system. Proceedings of the National Academy of Sciences, 90, 4665-4669.
155. Widnell KL, Self DW, Lane SB, Russell DS, Vaidya VA, Misererndino MJD, Rubin CS, Duman RS and Nestler EJ (1996) Regulation of CREB expression: in vivo evidence for a functional role in morphine action in the nucleus accumbens. Journal of Pharmacology and Experimental Therapeutics, 276, 306-315.
156. Xu M, Hu X, Cooper D, Moratalla R, Graybiel A, White F and Tonegawa S (1994a) Elimination of cocaine-induced hyperactivity and dopamine-mediated neurophysiological effects in dopamine D1 receptor mutant mice. Cell, 79, 945-955.
157. Xu M, Moratalla R, Gold L, Hiroi N, Koob G, Graybiel A and Tonegawa S (1994b) Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell, 79, 729-742.
158. Xu M, Caine S, Cooper D, Gold L, Graybiel A, Hu X, Koeltzow T, Koob G, Moratalla R, White F and Tonegawa S (1995) Analyses of dopamine D3 and D1 receptor mutant mice. Society for Neuroscience Abstracts, 21, 363.
159. Yakubov L, Deeva E, Zarytova V, Ivanova E, Ryte A, Yurchenko L and Vlassov V (1989) Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proceedings of the National Academy of Sciences, 86, 6456-6458.
160. Zang Z, Florijn W and Creese I (1994) Reduction in muscarinic receptors by antisense oligodeoxynucleotide. Biochemical Pharmacology, 48, 225-228.
161. 2 receptors: behavioral correlates. Neuroscience Letters, 161, 223-226.
162. 1 dopamine receptor-mediated behaviors in normal mice and in mice lesioned with 6-hydroxydopamine. Journal of Pharmacology and Experimental Therapeutics, 21, 1462-1470.
163. 2 dopamine receptors in mouse striatum. Journal of Pharmacology and Experimental Therapeutics, 268, 1015-1023.